Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
These catalysts could impact growth down the road.
Exelixis, a biotech firm, has two significant developments on the horizon, with both expected to arrive by March 2027. The first is the potential approval of zanzalintinib, a next-generation tyrosine kinase inhibitor, for metastatic colorectal cancer in combination with atezolizumab. The FDA is expected to make a decision by March 3, based on data showing the drug met one of the trial's primary endpoints - overall survival in patients.
The second catalyst is the release of data from a phase 3 trial comparing zanzalintinib to sunitinib in advanced non-clear cell renal cell carcinoma. Positive results from this trial could also lead to another regulatory submission. Exelixis currently relies heavily on its flagship product, Cabometyx, for revenue, but its focus is shifting towards zanzalintinib, which shows promise in its early-stage clinical trials.
However, investors should be aware of the risks involved, as negative FDA decisions or underwhelming trial results could negatively impact the stock price. Despite these risks, Exelixis' strong position in the market and extensive pipeline make it an intriguing prospect for those willing to take on some risk.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
